Brilinta Taiwan Post Approval Safety Study

Trial Identifier: D5130C00103
Sponsor: AstraZeneca
NCTID:: NCT02406248
Start Date: April 2015
Primary Completion Date: February 2017
Study Completion Date: February 2017
Condition: Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Taiwan Changhua City, Taiwan, 50006
Taiwan Hsinchu, Taiwan, 300
Taiwan Hualien City, Taiwan, 97002
Taiwan Kaohsiung, Taiwan, 81362
Taiwan Kaohsiung, Taiwan, 824
Taiwan Kaohsiung, Taiwan, 80756
Taiwan Kweishan Shiang, Taiwan, 333
Taiwan Niao-Song-Shiang, Taiwan, 833
Taiwan Taichung, Taiwan
Taiwan Tainan, Taiwan, 704
Taiwan Tainan County, Taiwan
Taiwan Taipei, Taiwan, 104
Taiwan Taipei, Taiwan, 11101
Taiwan Taipei, Taiwan, 114
Taiwan Taipei, Taiwan, 11217
Taiwan Taipei, Taiwan, 22060
Taiwan Taipei, Taiwan, 11220